-
Scipher Medicine Leadership to Present at the 40th Annual J.P. Morgan Healthcare Conference -
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis -
Scipher Medicine Appoints Richard Blackburn to its Advisory Board -
Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA Blood Test Since Its Launch A Year Ago -
Scipher Medicine Appoints Dr. Michael Elliott to its Science Advisory Board -
Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility - America’s Choice Provider Network Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care
-
Scipher Medicine® Appoints Sam Asgarian, M.D., MBA, Chief Medical Officer -
RxParadigm Partners with Scipher Medicine® to Support Medication Utilization, Improve Patient Outcomes, and Lower Costs for Rheumatoid Arthritis Care -
Scipher Medicine® to Present at the Jeffries London Healthcare Conference -
A molecular signature response classifier to predict inadequate response to tumor necrosis factor-α Inhibitors: the NETWORK-004 Prospective Observational Study - Scipher Medicine® to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
-
Discontinuation of TNFi treatment among Rheumatoid Arthritis patients with a molecular signature of non-response to tumor necrosis factor-ɑ inhibitor therapies -
A molecular signature response classifier predicts the likelihood of non-response to TNF inhibitor therapies in RA at 3 months -
GNS Healthcare and Scipher Medicine® Collaborate to Develop World’s First in silico Patient for Rheumatoid Arthritis